Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AssigneeG.D. Searle & Co.
InventorsBradley T. Keller, Samuel J. Tremont, Kevin C. Glenn, Robert E. Manning
Life of this patent
Estimating the term…
Abstract
Novel methods and combinations for the treatment and/or prophylaxis of a hyperlipidernic condition or disorder in a subject, wherein the methods comprise the administration of one or more HMG Co-A reductase inhibitors and one or more ASBT inhibitors selected from the specific group of compounds described herein, and the combinations comprise one or more HMG Co-A reductase inhibitors and one or more of said apical sodium co-dependent bile acid transport inhibitors.
Claims89
A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a subject which comprises administering a first amount of an apical sodium co-dependent bile acid transporter inhibitor and a second amount of an HMG Co-A reductase inhibitor wherein:
- the apical sodium co-dependent bile acid transporter inhibitor is selected from the group consisting of:
- 78 79 80 81
- and the pharmaceutically acceptable salts, esters, and prodrugs thereof;
- and
- the first and second amounts of said inhibitors together comprise a therapeutically effective amount of said inhibitors.
A composition comprising a first amount of an apical sodium co-dependent bile acid transporter inhibitor selected from the group consisting of
- 99 100 101 102
- and the pharmaceutically acceptable salts, esters and prodrugs thereof;
- a second amount of the HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof;
- and
- a pharrnaceutically acceptable carrier;
- wherein the first and second amounts of said inhibitors together comprise a therapeutically effective amount of said inhibitors.
A kit containing a first dosage form comprising an ASBT inhibitor and a second dosage form comprising an HMG Co-A reductase inhibitor, wherein the apical sodium co-dependent bile acid transporter inhibitor is selected from the group consisting of:
- 119 120 121 122
- and the pharmaceutically acceptable salts, esters and prodrugs thereof.
The compound having the formula
- 124
- and the pharmaceutically acceptable salts, esters and prodrugs thereof.
Dependencies are inferred from the claim text.